Edition:
India

Guerbet SA (GRBT.PA)

GRBT.PA on Paris Stock Exchange

55.70EUR
18 May 2018
Change (% chg)

€1.00 (+1.83%)
Prev Close
€54.70
Open
€54.90
Day's High
€55.80
Day's Low
€54.60
Volume
11,077
Avg. Vol
13,839
52-wk High
€87.65
52-wk Low
€50.00

Latest Key Developments (Source: Significant Developments)

Guerbet Expects 2018 Revenue In-Line With 2017
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Guerbet SA ::FOR 2018, EXPECTS REVENUE IN-LINE WITH 2017 AT CONSTANT EXCHANGE RATES.FOR 2018, EXPECTS EBITDA MARGIN DOWN BY C. 2 PERCENTAGE POINTS OF REVENUE COMPARED TO 2017.FOR 2020, AND TAKING INTO ACCOUNT INTERNAL BOOST INITIATIVES ONLY, TARGETS REVENUE BETWEEN €850M AND €900M AT CER.FOR 2020, AND TAKING INTO ACCOUNT INTERNAL BOOST INITIATIVES ONLY, TARGETS EBITDA MARGIN ABOVE 16.5%.FOR 2023 TARGETS REVENUE OF AROUND C. €1.0 BILLION AT CONSTANT EXCHANGE RATES AND AN EBITDA MARGIN ABOVE 20%.TARGETS NET CAPITAL EXPENDITURE OF C. €50M WITH ADDITIONAL ONE-OFF IMPACT OF C. €10M IN 2020 AND 2021.FOR 2023 TARGETS NET CAPITAL EXPENDITURE OF C. € 50 MILLION.TARGETS TO GENERATE €100M TO €150M OF REVENUE IN 2023 FROM COMPANIES ACQUIRED OVER 2018-2023 IN INTERVENTIONAL IMAGING.EXTERNAL BOOST INITIATIVES TO BE ACHIEVED OVER 2018-2023 ARE TARGETED TO CONTRIBUTE AN ADDITIONAL €150M TO €250M OF REVENUE BY 2023.GUERBET HAS IDENTIFIED PIPELINE OF REALISTIC TARGETS AND HAS AMBITION TO SIGN TWO ACQUISITIONS BEFORE END OF 2018.EXTERNAL BOOST INITIATIVES TO BE ACHIEVED OVER 2018-2023 ARE TARGETED TO HAVE AN OVERALL POSITIVE IMPACT ON EBITDA MARGIN.  Full Article

Guerbet Q1 Revenue Stable At 196.5 Million Euros
Wednesday, 18 Apr 2018 

April 18 (Reuters) - Guerbet SA ::Q1 REVENUE EUR 196.5 MILLION VERSUS EUR 197.3 MILLION YEAR AGO.FOR FY 2018 CONFIDENT IN FINANCIAL OBJECTIVES PRESENTED IN GEAR 2023 STRATEGIC PLAN.  Full Article

Guerbet Partners With Lausanne’S CHUV And CET To Launch Clinical Study
Friday, 13 Apr 2018 

April 13 (Reuters) - Guerbet SA ::PARTNERS WITH LAUSANNE’S CHUV AND CET TO LAUNCH A CLINICAL STUDY.PARTNERS TO WORK TO CLARIFY IMMUNOMODULATORY AND ACTIVATING MECHANISMS INDUCED BY A CTACE PROCEDURE IN 20 PATIENTS WITH HCC.  Full Article

Guerbet FY EBITDA Increased By 22.4 Percent To 130 Million Euros
Tuesday, 27 Mar 2018 

March 27 (Reuters) - GUERBET SA ::FY EBITDA INCREASED BY 22.4% TO EUR 130 MILLION.FY NET INCOME EUR 46.2 MILLION VERSUS EUR 28.9 MILLION YEAR AGO.‍WILL PROPOSE A DIVIDEND OF EUR 0.85 PER SHARE TO SHAREHOLDERS FOR FY ​.NET INCOME UP 60% AT EUR 46.2 MILLION.  Full Article

Guerbet Announces Acquisition Of Accurate Medical Therapeutics
Monday, 8 Jan 2018 

Jan 8 (Reuters) - GUERBET SA ::ANNOUNCES ACQUISITION OF ACCURATE MEDICAL THERAPEUTICS.TO ACQUIRE 100% OF ACCURATE'S SHARES WITH AN INITIAL PAYMENT OF € 19.5 MILLION AND ADDITIONAL PAYMENTS SPREAD OVER SEVERAL YEARS.TOTAL AMOUNT OF THE ACQUISITION MAY NOT EXCEED 57 MILLION EUROS.OPERATION IS EXPECTED TO START GENERATING REVENUE AT THE END OF 2018 AND TO BE ACCRETIVE AS OF THE 4TH QUARTER OF 2019.ACCURATE WILL RETAIN ITS STRUCTURE IN ISRAEL AND CONTINUE TO BE LED BY ITS CO-FOUNDER AND CEO, ERAN MILLER.  Full Article

Guerbet 9 months revenue up at ‍​601.4 million euros
Wednesday, 25 Oct 2017 

Oct 25 (Reuters) - GUERBET SA ::9 MONTHS REVENUE AT CURRENT EXCHANGE RATE EUR ‍​601.4 MILLION VERSUS EUR 568.4 MILLION YEAR AGO.MAINTAINS FY 2017 OBJECTIVES‍​.  Full Article

Guerbet to phase out Hexabrix and Optimark sales globally
Monday, 10 Jul 2017 

July 10 (Reuters) - GUERBET SA :REG-GUERBET ANNOUNCES PLANS TO STREAMLINE ITS CONTRAST MEDIA PORTFOLIO.WILL PHASE OUT SALES THROUGHOUT WORLD OF TWO PRODUCTS: HEXABRIX® (MEGLUMINE AND SODIUM IOXAGLATE) AND OPTIMARK® (GADOVERSETAMIDE)..‍SALES OF OPTIMARK® WILL END FIRST JULY 26, 2017 IN EUROPEAN UNION COUNTRIES​.‍OPTIMARK® PHASE OUT WILL BE PROGRESSIVELY IMPLEMENTED IN OTHER GEOGRAPHIC AREAS UNTIL END OF 2019​.‍HEXABRIX® SALES IN EUROPE, ASIA AND LATIN AMERICA WILL PROGRESSIVELY CEASE, BY END OF 2019 AT LATEST​.  Full Article

Guerbet Q4 revenue rises to 207.4 million euros
Wednesday, 15 Feb 2017 

Guerbet SA : Q4 revenue 207.4 million euros ($219.93 million) versus 193.6 million euros year ago .Outlook for 2017: resumption of growth.  Full Article

Guerbet H1 net income down at 17.3 million euros
Wednesday, 28 Sep 2016 

Guerbet SA : H1 net income 17.3 million euros ($19.4 million) versus 20.5 million euros year ago . H1 EBITDA 55.3 million euros versus 46.6 million euros year ago .Confirms its target for the full year of generating revenue within a range of +/-3 pct of 2015.  Full Article

Guerbet H1 revenue down at 376.7 million euros
Thursday, 28 Jul 2016 

Guerbet SA : H1 revenue 376.7 million euros ($417.31 million) versus 397.8 million euros year ago .2016 outlook: stabilization of sales at +/- 3 pct already achieved and confirmation of annual targets.  Full Article

BRIEF-Guerbet Announces Acquisition Of A New Microsphere Technology

* GUERBET ANNOUNCES THE ACQUISITION OF A NEW MICROSPHERE TECHNOLOGY TO STRENGTHEN ITS INTERVENTIONAL IMAGING RANGE